Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)

Phase 4

Completed

• Conditions: Benign Prostatic Hyperplasia (BPH)
• Interventions: Drug: Permixon® 160 mg; Drug: Tamsulosine Arrow LP; Drug: Placebo matching Permixon® 160 mg; Drug: Placebo matching Tamsulosine Arrow LP

• Registration Number: NCT01604811
• Lead Sponsor: Pierre Fabre Medicament

Brief Summary

Inflammation is reported as one of the most recent hypotheses to explain BPH. Recent published works pointed out that urine and serum markers could be used for detection of prostatic inflammation.

The aim of the study is to assess the activity on inflammation biomarkers (serum and urine inflammation markers) of Permixon® 160 mg hard capsule and Tamsulosine Arrow LP in the treatment of urinary symptoms related to BPH.

The potential links between serum and urinary markers of inflammation and BPH clinical symptoms at baseline and on treatment will be explored.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-05-22
• Study First Submitted QC: 2012-05-23
• Study First Posted: 2012-05-24
• Study Start: 2012-06
• Status Verified: 2013-07
• Primary Completion: 2013-10
• Study Completion: 2013-10
• Last Update Submitted: 2014-01-14
• Last Update Posted: 2014-01-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 206

Inclusion Criteria

• Male patient

• Between 45 and 85 years old.

• Patient with bothersome lower urinary tract symptoms such as pollakiuria (daytime or night time), urgency, sensation of incomplete voiding, delayed urination or weak stream, existing for over 12 months

• I-PSS ≥ 10 at selection visit and ≥ 12 at randomisation visit (visit 2)

• Stable patient's disease at randomisation defined as an absolute difference of 2 or less on I-PSS between selection and randomisation visits (visit 1 and visit 2)

• I-PSS QoL score ≥ 3 evaluated at selection and randomisation visits,

• 5 mL/s ≤ maximum urinary flow rate < 15 mL/s for a voided volume ≥ 150 mL and ≤ 500 mL evaluated at randomisation visit (2 measurements if necessary)

• Prostatic volume ≥30 cm³ determined by transrectal ultrasound at randomisation visit (visit 2)

• Serum total PSA at randomisation visit (visit 2) :

  • 4 ng/mL
  • 10 ng/mL and Prostate Specific Antigen (free) / Prostate Specific Antigen (total) ≥ 25% or negative prostate biopsy within the past 6 months prior to selection visit.

• Patient able to understand and sign the informed consent and understand and fill in self-questionnaires

Exclusion Criteria

• Post-void residual urine volume > 200 mL (by suprapubic ultrasound) at randomisation visit (visit 2).

• Urological history :

  • Urethral stricture disease and/or bladder neck disease
  • Active (at selection and randomisation visits) or recent (< 3 months) or recurrent urinary tract infection
  • Indication of BPH surgery
  • Stone in bladder or urethra
  • Acute or chronic (documented) prostatitis
  • Prostate and cancer cancer treated or untreated
  • Interstitial cystitis (documented by symptoms and/or biopsy)
  • Active upper tract stone disease causing symptoms

• Patient with history of surgery of the prostate, bladder neck or pelvic region

• Any local and/or systemic inflammation disorders at selection and randomisation visit

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tested product	Permixon® 160 mg	-
Comparator	Placebo matching Permixon® 160 mg	-
Comparator	Tamsulosine Arrow LP	-
Tested product	Placebo matching Tamsulosine Arrow LP	-

Primary Outcome Measures

Name	Time	Method
Change from baseline of Inflammation Biomarkers	Day 1 (baseline), Day 30, Day 90	"Inflammation biomarkers assay in patients suffering from Benign Prostatic Hyperplasia at Day 1, Day 30 and Day 90 : * Urine inflammation markers \[mRNA (messenger RiboNucleic Acid) and proteins\] on the first urine flow after digital rectal examination; * Serum inflammation markers (C-Reactive Protein and Sedimentation Rate) "

Secondary Outcome Measures

Name	Time	Method
Change from baseline of urinary symptoms	Day 1 (baseline), Day 30, Day 90	Urinary symptoms assessed by International Prostate Symptom Score (I-PSS) (self-administered questionnaire)
Change from baseline of quality of life	Day 1 (baseline), Day 30, Day 90	Impact of symptoms on quality of life on the basis of the I-PSS quality of life question scored by the patient
Change from baseline of sexual activity	Day 1 (baseline), Day 30, Day 90	Sexual activity assessed by the Male Sexual Function questionnaire (MSF-4) (self-administered questionnaire)
Change from baseline of maximum urinary flow rate	Day 1 (baseline), Day 30, Day 90	Uroflowmetry performed using an electronic flow meter.
Change from baseline of prostate volume	Day 1 (baseline), Day 30, Day 90	Prostate volume determined by transrectal ultrasound
Change from baseline of post-void residual urine volume (PVR)	Day 1 (baseline), Day 30, Day 90	Post-void residual urine volume determined by suprapubic ultrasound.
Number of adverse events	up to 90 days	Number of adverse events